<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Risk of infections in patients with chronic lymphocytic leukemia
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Risk of infections in patients with chronic lymphocytic leukemia
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Risk of infections in patients with chronic lymphocytic leukemia
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Vicki A Morrison, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Eric Bow, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Milana Bogorodskaya, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 12, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1198722">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Infections have a major impact on the clinical course of patients with chronic lymphocytic leukemia (CLL). Patients with CLL have underlying abnormalities in immune function related to the primary disease process in addition to immune defects related to the specific antileukemic therapies administered. The spectrum of infections in CLL patients has evolved with the introduction of therapies such as the purine analogs and newer targeted therapies (phosphatidylinositol 3-kinase and Bruton tyrosine kinase inhibitors).
        </p>
        <p>
         The immune defects related to CLL and its therapy as well as the spectrum of infectious complications will be reviewed here. The approach to infection prevention in patients with CLL is reviewed separately. The management and complications of CLL are also discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1405.html" rel="external">
          "Prevention of infections in patients with chronic lymphocytic leukemia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4545.html" rel="external">
          "Overview of the treatment of chronic lymphocytic leukemia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/83749.html" rel="external">
          "Selection of initial therapy for symptomatic or advanced chronic lymphocytic leukemia/small lymphocytic lymphoma"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4520.html" rel="external">
          "Treatment of relapsed or refractory chronic lymphocytic leukemia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4504.html" rel="external">
          "Overview of the complications of chronic lymphocytic leukemia"
         </a>
         .)
        </p>
        <p>
         The immune defects caused by the drugs and biologics used for CLL and other diseases is also reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/3939.html" rel="external">
          "Secondary immunodeficiency induced by biologic therapies"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1198484">
         <span class="h1">
          IMMUNE DEFECTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with chronic lymphocytic leukemia (CLL) have inherent immune defects in humoral and cell-mediated immunity that are related to the primary disease process, including hypogammaglobulinemia, abnormalities in T cell subsets, and defects in complement activity and neutrophil/monocyte function [
         <a href="#rid1">
          1,2
         </a>
         ]. Therapy-related immunosuppression has further impact on immune function [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1198496">
         <span class="h2">
          Humoral immunity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypogammaglobulinemia is the most predominant inherent immune defect in CLL patients, with subtypes immunoglobulin (Ig)G3 and IgG4 particularly affected. Hypogammaglobulinemia is related to defective functioning of T cells and non-clonal CD5-negative B cells. Hypogammaglobulinemia becomes more pronounced with longer disease duration and advanced-stage disease. There is generally no reversal in this defect, even with response to therapy. However, in one report,
         <a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">
          ibrutinib
         </a>
         therapy resulted in partial reconstitution of humoral immunity, with an increase in IgA levels [
         <a href="#rid4">
          4
         </a>
         ]. Although an association between hypogammaglobulinemia and infection frequency and survival has been demonstrated, there is no consistent correlation between a specific immunoglobulin class deficiency and infection risk [
         <a href="#rid1">
          1,5,6
         </a>
         ].
        </p>
        <p>
         The immunoglobulin heavy chain variable region (
         <em>
          IgV
         </em>
         <em>
          <sub>
           H
          </sub>
         </em>
         ) gene may be mutated or unmutated in patients with CLL. Patients with unmutated
         <em>
          IgV
         </em>
         <em>
          <sub>
           H
          </sub>
         </em>
         genes tend to have a poorer prognosis than those with mutated
         <em>
          IgV
         </em>
         <em>
          <sub>
           H
          </sub>
         </em>
         genes. The impact of
         <em>
          IgV
         </em>
         <em>
          <sub>
           H
          </sub>
         </em>
         mutational status on humoral immunity and infections has been evaluated, with conflicting results [
         <a href="#rid7">
          7,8
         </a>
         ]. In a study that included 33 patients with CLL, there were no significant differences in the levels of immunoglobulins or mannose-binding lectin, immune response to
         <em>
          Haemophilus influenzae
         </em>
         type b vaccination, or infection rate among patients with mutated versus unmutated
         <em>
          IgV
         </em>
         <em>
          <sub>
           H
          </sub>
         </em>
         gene status [
         <a href="#rid7">
          7
         </a>
         ]. In contrast, in a retrospective review of 280 patients with CLL, those with unmutated
         <em>
          IgV
         </em>
         <em>
          <sub>
           H
          </sub>
         </em>
         <sub>
         </sub>
         genes had a significantly shorter time to first infection (31 versus 62 months) and significantly higher infection-related mortality than patients with mutated
         <em>
          IgV
         </em>
         <em>
          <sub>
           H
          </sub>
         </em>
         genes, although immunoglobulin levels were comparable [
         <a href="#rid8">
          8
         </a>
         ]. Patients with p53 abnormalities, as well as CD38 positivity, had a significantly shorter time to first infection; zeta-chain-associated protein kinase 70 (ZAP-70) levels had no impact on occurrence.
        </p>
        <p>
         The most common site of infection in CLL patients is the respiratory tract, which may be related to serum IgA and IgG4 deficiencies and possibly to mucosal immune defects [
         <a href="#rid6">
          6
         </a>
         ]. It is not clear if mucosal immunity is regulated independently of systemic immunity or if mucosal B cells are part of the malignant B cell clone. The integrity of mucosal immune function and the relationship between systemic and mucosal immune dysfunction are not well delineated. In a report of serum and mucosal (salivary) immunoglobulin levels measurement in CLL patients, salivary IgM levels were profoundly decreased in hypogammaglobulinemic CLL patients, but no differences were found in salivary IgG or IgA levels among CLL patients versus controls [
         <a href="#rid6">
          6
         </a>
         ]. However, no correlation between salivary immunoglobulin levels and infection occurrence was found.
        </p>
        <p class="headingAnchor" id="H1198502">
         <span class="h2">
          Cell-mediated immunity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although CLL patients have inherent defects in various parameters of cell-mediated immunity and complement activity, their impact on infection risk has not been examined. These defects may be related to transforming growth factor beta (TGF-beta) secretion by CLL B cells, which inhibits B cell proliferation, as well as release of circulating interleukin (IL-)2 receptor, which binds endogenous IL-2, resulting in down-regulation of T cell function.
        </p>
        <p>
         CD8-positive T cells secrete IL-4, which induces bcl-2 protein expression, possibly contributing to CLL pathogenesis and disease progression. As with B cell defects, T cell defects are more pronounced with advanced-stage disease.
        </p>
        <p class="headingAnchor" id="H1198508">
         <span class="h2">
          Complement
         </span>
         <span class="headingEndMark">
          —
         </span>
         Decreased levels of at least one component of complement, especially properdin, are found in most patients with CLL [
         <a href="#rid1">
          1
         </a>
         ]. Defects in complement activation and binding and reduced expression of the complement receptors, CR1 and CR2, on CLL B cells have also been found.
        </p>
        <p class="headingAnchor" id="H1198514">
         <span class="h2">
          Innate immunity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Quantitative and qualitative neutrophil and monocyte defects are found in CLL patients. The absolute neutrophil count is normal to slightly decreased in untreated patients. Defects in neutrophil phagocytic and bactericidal activity, including decreased C5a-induced chemotaxis, have been demonstrated, as well as deficiencies in monocyte levels of b-glucuronidase, lysozyme, and myeloperoxidase [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1200223">
         <span class="h1">
          SPECTRUM OF INFECTIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The spectrum of infections in CLL patients has changed over the past several decades with the introduction of CLL therapies that have specific effects on immune function, particularly on cell-mediated immunity. The infectious complications seen in these patients have evolved in relation to the specific agents used and will be discussed below in relation to the various classes of CLL therapy.
        </p>
        <p>
         Treatment-naïve patients are at increased risk for bacterial infections caused by common pathogens, such as
         <em>
          Staphylococcus aureus
         </em>
         ,
         <em>
          Streptococcus pneumoniae
         </em>
         ,
         <em>
          Haemophilus influenzae
         </em>
         ,
         <em>
          Escherichia coli
         </em>
         ,
         <em>
          Klebsiella pneumoniae
         </em>
         , and
         <em>
          Pseudomonas aeruginosa
         </em>
         [
         <a href="#rid1">
          1
         </a>
         ]. Recurrent bacterial infections with a mucosal origin (respiratory tract, urinary tract) are also common.
        </p>
        <p class="headingAnchor" id="H1200229">
         <span class="h2">
          Alkylating agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         For many years, standard therapy for CLL patients was
         <a class="drug drug_general" data-topicid="9240" href="/z/d/drug information/9240.html" rel="external">
          chlorambucil
         </a>
         (or alternatively,
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         ) given alone or in combination with glucocorticoids. As in treatment-naïve patients, the majority of infections in patients treated with an alkylating agent are bacterial, caused by common pathogens such those described above [
         <a href="#rid1">
          1
         </a>
         ]. Recurrent bacterial infections with a mucosal origin (respiratory tract, urinary tract) are common. Fungal and viral infections occur infrequently. In more recent times,
         <a class="drug drug_general" data-topicid="9323" href="/z/d/drug information/9323.html" rel="external">
          bendamustine
         </a>
         is used in combination with
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         . However, no specific spectrum of infectious complications has emerged with this therapeutic combination.
        </p>
        <p class="headingAnchor" id="H82248400">
         <span class="h2">
          Purine analogs
         </span>
        </p>
        <p class="headingAnchor" id="H1200235">
         <span class="h3">
          Fludarabine
         </span>
         <span class="headingEndMark">
          —
         </span>
         With the use of purine analogs (eg,
         <a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">
          fludarabine
         </a>
         ), which result in quantitative and qualitative T cell abnormalities, a wider spectrum of infectious complications has emerged [
         <a href="#rid9">
          9-15
         </a>
         ]. Inhibition of cytokine-induced activation of STAT-1- and STAT-1-dependent gene transcription results in decreased peripheral blood T cell counts, which occurs early in treatment and persists for up to two years after discontinuation of therapy [
         <a href="#rid16">
          16
         </a>
         ]. A greater impact is seen on CD4+ T cells than CD8+ T cells or NK cells. Decreased B cell and monocyte counts also occur.
        </p>
        <p>
         In addition to common bacterial infections, opportunistic infections caused by organisms such as
         <em>
          Listeria,
         </em>
         mycobacteria,
         <em>
          Nocardia, Candida
         </em>
         ,
         <em>
          Aspergillus
         </em>
         ,
         <em>
          Cryptococcus
         </em>
         ,
         <em>
          Pneumocystis
         </em>
         , and herpesviruses (herpes simplex virus [HSV], varicella-zoster virus [VZV], and cytomegalovirus [CMV]) have been reported
         <em>
         </em>
         [
         <a href="#rid10">
          10-14
         </a>
         ]. The addition of glucocorticoids to
         <a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">
          fludarabine
         </a>
         increases the risk of these opportunistic infections and is therefore generally avoided [
         <a href="#rid10">
          10,13,15
         </a>
         ]. HSV and VZV infections, the majority being localized infections, are more common in patients receiving single-agent fludarabine than in those receiving
         <a class="drug drug_general" data-topicid="9240" href="/z/d/drug information/9240.html" rel="external">
          chlorambucil
         </a>
         [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
         Infections are most common during the first several cycles of therapy and are relatively uncommon after discontinuation of therapy in responding patients [
         <a href="#rid10">
          10
         </a>
         ]. Risk factors for infection in patients receiving
         <a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">
          fludarabine
         </a>
         include poor therapeutic response, advanced disease stage, receipt of prior CLL therapy, elevated lactic dehydrogenase (LDH), and renal insufficiency [
         <a href="#rid10">
          10-12,15,17-19
         </a>
         ]. In a trial in which patients received initial CLL therapy with fludarabine,
         <a class="drug drug_general" data-topicid="9240" href="/z/d/drug information/9240.html" rel="external">
          chlorambucil
         </a>
         , or both agents, a low baseline IgG level was a risk factor for infection [
         <a href="#rid14">
          14
         </a>
         ]. Advanced age and a decreased creatinine clearance were risk factors only in patients receiving both agents. No association between infection and response to therapy or advanced-stage disease was observed. In a large retrospective review, risk factors for major infections identified on multivariate analysis included the number of prior regimens (risk ratio [RR] 1.8, 95% CI 1.2-8.0) and hemoglobin &lt;12 g/dL (RR 0.6, 95% CI 0.5-0.8) [
         <a href="#rid18">
          18
         </a>
         ]. Age and renal function had no impact on infection risk.
        </p>
        <p>
         The risk and spectrum of infection in patients treated with
         <a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">
          fludarabine
         </a>
         compared with conventional regimens based on alkylating agents have been examined [
         <a href="#rid14">
          14,20,21
         </a>
         ]. In one trial, patients receiving fludarabine and
         <a class="drug drug_general" data-topicid="9240" href="/z/d/drug information/9240.html" rel="external">
          chlorambucil
         </a>
         had significantly more infections than those receiving either agent alone [
         <a href="#rid14">
          14
         </a>
         ]. Those receiving fludarabine alone had more major infections and herpesvirus infections compared with patients treated with chlorambucil alone. Only three
         <em>
          Pneumocystis
         </em>
         infections and no
         <em>
          Aspergillus
         </em>
         infections were observed. Similarly, in a meta-analysis of single-agent fludarabine or alkylating agent-based therapy trials, grade 3/4 (severe) infections were more common with fludarabine therapy [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
         Infections with fludarabine-cyclophosphamide combination therapy have also been evaluated [
         <a href="#rid22">
          22-25
         </a>
         ]. In a randomized intergroup trial of initial CLL therapy with this combination plus myeloid growth factor support and antiviral prophylaxis or single-agent
         <a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">
          fludarabine
         </a>
         , infection rates less than 10 percent were reported in both arms; all patients received
         <em>
          Pneumocystis
         </em>
         prophylaxis [
         <a href="#rid23">
          23
         </a>
         ]. The German CLL Study Group studied first-line fludarabine-cyclophosphamide therapy in a phase II trial as well as in a randomized trial in younger CLL patients, comparing it with single-agent fludarabine [
         <a href="#rid24">
          24,25
         </a>
         ]. In the latter trial, the occurrence of severe and opportunistic infections was comparable (fludarabine 33 percent; fludarabine-cyclophosphamide 40 percent) [
         <a href="#rid26">
          26
         </a>
         ]. However, dose reductions due to myelosuppression were more common with the combination, which may have impacted the infection rate. In previously treated patients, 57 percent receiving fludarabine-cyclophosphamide had infections or fever of unknown origin, including 26 percent caused by herpesviruses and 7 percent caused by fungal pathogens [
         <a href="#rid27">
          27
         </a>
         ]. The incidence of infection during the first three cycles of therapy was 74 percent. Epstein-Barr virus-associated lymphoproliferative disorders have been reported in patients who received fludarabine-cyclophosphamide followed by autologous stem cell transplant [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1201378">
         <span class="h3">
          Other purine analogs
         </span>
         <span class="headingEndMark">
          —
         </span>
         As with
         <a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">
          fludarabine
         </a>
         , treatment with
         <a class="drug drug_general" data-topicid="9272" href="/z/d/drug information/9272.html" rel="external">
          cladribine
         </a>
         (2-chlorodeoxyadenosine) or
         <a class="drug drug_general" data-topicid="9756" href="/z/d/drug information/9756.html" rel="external">
          pentostatin
         </a>
         (deoxycoformycin) also results in quantitative T cell subset abnormalities that persist for up to one to two years after therapy discontinuation. Receipt of prior therapy was a significant risk factor for infection in younger patients receiving cladribine (45 versus 26 percent) [
         <a href="#rid29">
          29
         </a>
         ]. In a series of older adult patients treated with cladribine, the infection rate was 16 percent [
         <a href="#rid30">
          30
         </a>
         ]. In a phase II trial of cladribine therapy in fludarabine-refractory CLL patients, severe infections occurred in 43 percent [
         <a href="#rid31">
          31
         </a>
         ]. Bacterial infections were most common, although cases of herpesvirus infection, toxoplasmosis, and candidal esophagitis were also reported. Opportunistic infections such as disseminated herpes zoster and pulmonary aspergillosis have also been reported in patients with refractory CLL receiving cladribine [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
         In a large series of CLL patients treated with
         <a class="drug drug_general" data-topicid="9272" href="/z/d/drug information/9272.html" rel="external">
          cladribine
         </a>
         alone or with
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         , infections and fever of unknown origin occurred more often in previously treated patients than in treatment-naïve patients (49 versus 38 percent) [
         <a href="#rid33">
          33
         </a>
         ]. Herpesvirus infections also occurred more often in previously treated patients (25 versus 20 percent). In a trial in which patients were randomly assigned to initial therapy with cladribine or
         <a class="drug drug_general" data-topicid="9240" href="/z/d/drug information/9240.html" rel="external">
          chlorambucil
         </a>
         plus prednisone, neutropenic fever or fever of unknown origin was more common with cladribine therapy (56 versus 40 percent) as were herpesvirus infections (21 versus 11 percent) [
         <a href="#rid34">
          34
         </a>
         ]. In a phase II trial of
         <a class="drug drug_general" data-topicid="9756" href="/z/d/drug information/9756.html" rel="external">
          pentostatin
         </a>
         for both previously treated and treatment-naïve CLL patients, infections occurred in over 50 percent of patients, especially in heavily pretreated patients [
         <a href="#rid35">
          35
         </a>
         ]. Opportunistic infections (herpesviruses,
         <em>
          Candida
         </em>
         ,
         <em>
          Pneumocystis
         </em>
         ) occurred in 26 percent of patients. The use of initial CLL therapy with pentostatin, chlorambucil, and prednisone resulted in grade 3 infections in 31 percent of patients, including herpes zoster in 20 percent of patients [
         <a href="#rid36">
          36
         </a>
         ]. The administration of pentostatin,
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         , and
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         to previously treated CLL patients resulted in a 28 percent incidence of severe infections [
         <a href="#rid37">
          37
         </a>
         ]. This incidence was only 10 percent in treatment-naïve patients [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1201390">
         <span class="h2">
          Anti-CD20 monoclonal antibodies
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rituximab
         </strong>
         –
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          Rituximab
         </a>
         , an anti-CD20 monoclonal antibody that causes a transient reduction in the B cell count, has been used as single-agent therapy for CLL but is more commonly used as part of combination therapy. Grade 3 or 4 (severe) infections and opportunistic infections are uncommon with rituximab monotherapy [
         <a href="#rid39">
          39
         </a>
         ]. However, in a phase II trial of concurrent versus sequential
         <a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">
          fludarabine
         </a>
         plus rituximab in 104 previously untreated CLL patients, the severe infection rate was 20 percent [
         <a href="#rid40">
          40
         </a>
         ]. Opportunistic infections, mainly localized herpesvirus infections, occurred in 16 percent of patients receiving concurrent fludarabine-rituximab and 26 percent receiving sequential therapy. With these agents, only two cases of
         <em>
          Pneumocystis
         </em>
         pneumonia were seen. Rituximab has been associated with reactivation of hepatitis B among patients positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (anti-HBc) [
         <a href="#rid41">
          41
         </a>
         ]. Rituximab has also been associated with progressive multifocal leukoencephalopathy (PML) [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ofatumumab
         </strong>
         –
         <a class="drug drug_general" data-topicid="9523" href="/z/d/drug information/9523.html" rel="external">
          Ofatumumab
         </a>
         is another anti-CD20 monoclonal antibody utilized for CLL therapy, and its profile of infectious complications are similar to that seen with
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         [
         <a href="#rid43">
          43
         </a>
         ]. Hepatitis B reactivation and PML may occur [
         <a href="#rid44">
          44,45
         </a>
         ]. Infections in patients receiving ofatumumab are usually grade 1 or 2; among grade 3 or 4 infections, pneumonia and other respiratory tract infections are most common [
         <a href="#rid46">
          46,47
         </a>
         ]. As an example, in a trial comparing ofatumumab and
         <a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">
          ibrutinib
         </a>
         in relapsed/refractory CLL patients, overall infection rates were lower in the ofatumumab group (54 percent versus 70 percent) but severe infection rates were similar (22 percent versus 24 percent) [
         <a href="#rid48">
          48
         </a>
         ]. In another study of ofatumumab, 189 infections occurred in 92 patients, including 13 fatal infections, with one episode of Fusarium infection and one of PML [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="91388" href="/z/d/drug information/91388.html" rel="external">
          Obinutuzumab
         </a>
         – Obinutuzumab is a type 2 anti-CD20 monoclonal antibody that is approved in combination with either
         <a class="drug drug_general" data-topicid="115440" href="/z/d/drug information/115440.html" rel="external">
          acalabrutinib
         </a>
         or
         <a class="drug drug_general" data-topicid="107696" href="/z/d/drug information/107696.html" rel="external">
          venetoclax
         </a>
         for CLL therapy [
         <a href="#rid49">
          49
         </a>
         ]. Its profile of infectious complications are similar to that seen with
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         [
         <a href="#rid43">
          43
         </a>
         ]. In preliminary data, most infections occurring with obinutuzumab were bacterial in origin, with opportunistic infections being uncommon [
         <a href="#rid49">
          49,50
         </a>
         ]. Grade 3 to 5 infection rates range from 5 to 19 percent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fludarabine
         </strong>
         <strong>
          -
         </strong>
         <strong>
          cyclophosphamide
         </strong>
         <strong>
          -
         </strong>
         <strong>
          rituximab
         </strong>
         <strong>
          combination
         </strong>
         – The fludarabine-cyclophosphamide-rituximab regimen has been used as initial and salvage CLL therapy, generally with antiviral and
         <em>
          Pneumocystis
         </em>
         prophylaxis [
         <a href="#rid51">
          51,52
         </a>
         ]. In a large series of treatment-naïve patients, although one-third had at least one infection and 10 percent had fever of unknown origin, only 3 percent had major infections [
         <a href="#rid51">
          51
         </a>
         ]. Reactivation of herpes simplex or varicella-zoster virus occurred in 5 percent of patients, but no cases occurred in those receiving antiviral prophylaxis. A small number of opportunistic infections (
         <em>
          Pneumocystis
         </em>
         ,
         <em>
          Aspergillus
         </em>
         ,
         <em>
          Candida glabrata
         </em>
         , CMV) occurred. With fludarabine-cyclophosphamide-rituximab therapy in the setting of relapsed or refractory disease, major infections (including one case of CMV pneumonitis) occurred in 16 percent of patients and minor infections occurred in 18 percent [
         <a href="#rid52">
          52
         </a>
         ]. Major infection incidence was comparable in fludarabine-sensitive and fludarabine-refractory patients.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1201396">
         <span class="h2">
          Alemtuzumab
         </span>
         <span class="headingEndMark">
          —
         </span>
         Therapy with
         <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">
          alemtuzumab
         </a>
         , an anti-CD52 monoclonal antibody, is associated with profound defects in cell-mediated immunity as well as neutropenia [
         <a href="#rid53">
          53-63
         </a>
         ]. Reductions in B, T, and NK cells occur early in treatment and persist for four to nine months after discontinuation of therapy. There is no correlation between the severity or duration of immunosuppression and the alemtuzumab cumulative dose or route of administration, although nonresponders are at greater risk of infection [
         <a href="#rid53">
          53,58,59,64
         </a>
         ]. Alemtuzumab has been associated with a wide range of infections, including bacterial, viral, fungal, and protozoal infections [
         <a href="#rid56">
          56,60
         </a>
         ]. CMV reactivation/disease is the most significant infectious complication occurring with alemtuzumab. The incidence of symptomatic CMV infection with alemtuzumab therapy ranges from 4 to 29 percent, with a peak onset four to six weeks after initiation of therapy [
         <a href="#rid65">
          65
         </a>
         ]. CMV infections are more common in patients who have received previous treatment for CLL and are uncommon after discontinuation of therapy. Although alemtuzumab in combination with
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         is approved as salvage therapy for CLL patients, use of this drug is limited because of these serious and common infectious complications [
         <a href="#rid57">
          57,61,63,65-69
         </a>
         ], as well as the availability of newer targeted agents, such as Bruton tyrosine kinase (BKI) inhibitors, with better adverse effect profiles.
        </p>
        <p class="headingAnchor" id="H13885161">
         <span class="h2">
          Bruton tyrosine kinase inhibitors
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ibrutinib
         </strong>
         –
         <a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">
          Ibrutinib
         </a>
         was the first Bruton tyrosine kinase (BTK) inhibitor approved for therapy of CLL. This agent causes hypogammaglobulinemia and inhibition of B cell signaling [
         <a href="#rid70">
          70
         </a>
         ]. The most common infections are infections of the upper respiratory tract, with the majority being grade 1 or 2 infections [
         <a href="#rid66">
          66,71
         </a>
         ]. Other less common infections include sinusitis, cellulitis, and urinary tract infections, also mostly grade 1 or 2 infections.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Serious infections occur in around 10 to 20 percent of patients receiving
         <a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">
          ibrutinib
         </a>
         . In one large series, the use of ibrutinib salvage therapy was complicated by more major infections than previous chemoimmunotherapy, and these infections required either hospitalization or intravenous antimicrobial therapy [
         <a href="#rid68">
          68
         </a>
         ]. In another study, a 17 percent rate of grade 3 or 4 pneumonia was reported in a series of relapsed/refractory CLL patients receiving therapy with ibrutinib plus
         <a class="drug drug_general" data-topicid="9523" href="/z/d/drug information/9523.html" rel="external">
          ofatumumab
         </a>
         [
         <a href="#rid67">
          67
         </a>
         ]. In a retrospective study of 378 patients receiving ibrutinib for CLL or non-Hodgkin lymphoma, serious infections developed in 43 (11.4 percent), primarily during the first year of therapy [
         <a href="#rid72">
          72
         </a>
         ]. Of those with serious infections, 23 (53.5 percent) developed serious bacterial infections, 16 (37.2 percent) developed invasive fungal infections, and 4 (9.3 percent) developed viral infections.
        </p>
        <p>
        </p>
        <p>
         <a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">
          Ibrutinib
         </a>
         is also associated with serious opportunistic infections, with one large retrospective study reporting an incidence of four percent [
         <a href="#rid69">
          69,73
         </a>
         ]. Invasive aspergillus in particular is one of the most common opportunistic infections seen in this patient population [
         <a href="#rid74">
          74-78
         </a>
         ].
        </p>
        <p>
         Aspergillosis is the most common invasive fungal infection that occurs in patients with CLL taking
         <a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">
          ibrutinib
         </a>
         [
         <a href="#rid72">
          72,73,77,79
         </a>
         ]. In a retrospective study of 566 patients who received ibrutinib for the treatment of a hematologic malignancy, 23 (4.1 percent) patients developed infection, 12 of whom had invasive aspergillosis [
         <a href="#rid73">
          73
         </a>
         ]. In another retrospective study of 378 patients receiving ibrutinib for CLL or non-Hodgkin lymphoma where 43 (11.4 percent) patients developed infections, there were eight cases of proven or probable aspergillosis [
         <a href="#rid72">
          72
         </a>
         ]. Two involved the brain in addition to the lungs, one involved the pleura, and five were limited to the lungs. Infection resulted in death in 6 of the 43 patients (14 percent). Risk factors for invasive fungal infections among patients who received ibrutinib included receipt of ≥3 prior anti-tumor regimens and receipt of glucocorticoids at any time during the course of ibrutinib. However, the majority of patients who developed invasive fungal infections while receiving ibrutinib (62.5 percent) lacked typical risk factors (eg, neutropenia, lymphopenia, receipt of glucocorticoids). In a small retrospective study of 33 patients with relapsed or refractory chronic lymphocytic leukemia, mantle cell lymphoma, or Waldenström's macroglobulinemia treated with ibrutinib (as a single agent or in combination) who developed invasive fungal infection, median time from initiation of therapy to fungal infection diagnosis was 3 (range, 1 to 30) months [
         <a href="#rid79">
          79
         </a>
         ].
        </p>
        <p>
         In a series of 96 patients receiving
         <a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">
          ibrutinib
         </a>
         as the sole agent for CLL, five were reported to
         <em>
         </em>
         have
         <em>
          Pneumocystis
         </em>
         pneumonia [
         <a href="#rid80">
          80
         </a>
         ]. Four of the five patients had not been treated previously for CLL and all had a CD4 count &gt;500/mm3and an IgG level &gt;500 mg/dL. All five had a positive polymerase chain reaction (PCR) assay from bronchoalveolar lavage fluid and one also had a positive direct fluorescence antibody stain. Gomori-methenamine silver staining was negative in all patients. A limitation of the study is that positive PCR results can be due to ei
         <em>
          ther Pneumocystis
         </em>
         infection or colonization. All of the infections were grade ≤2 and resolved with oral therapy with
         <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">
          trimethoprim-sulfamethoxazole
         </a>
         . The approac
         <em>
          h to Pneumocystis
         </em>
         prophylaxis is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/1405.html" rel="external">
          "Prevention of infections in patients with chronic lymphocytic leukemia", section on 'Bruton tyrosine kinase and phosphatidylinositol 3-kinase inhibitors'
         </a>
         .)
        </p>
        <p>
         Other reported opportunistic infections include disseminated cryptococcosis, histoplasmosis, blastomycosis, fusariosis, hepatitis B virus reactivation, Staphylococcus aureus meningitis, miliary tuberculosis, mucormycosis, amebic encephalitis, cutaneous Mycobacterium chelonae infection, progressive multifocal leukoencephalopathy, and disseminated VZV infection [
         <a href="#rid69">
          69,72,75,78-95
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pirtobrutinib
         </strong>
         –
         <a class="drug drug_general" data-topicid="140692" href="/z/d/drug information/140692.html" rel="external">
          Pirtobrutinib
         </a>
         has very recently been approved for salvage therapy of chronic lymphocytic leukemia, after receipt of at least two lines of therapy, including a BKI and BCL-2 inhibitor. It was initially approved for salvage therapy of mantle cell lymphoma [
         <a href="#rid96">
          96
         </a>
         ]. In the mantle cell lymphoma trial, grade ≥3 infections occurred in 28 (17.1 percent) patients, with the most common infection of any grade observed being pneumonia (10.4 percent, n = 17) and COVID-19–related pneumonia (3 percent, n = 5).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2671438">
         <span class="h2">
          Phosphatidylinositol 3-kinase inhibitors
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="96416" href="/z/d/drug information/96416.html" rel="external">
          Idelalisib
         </a>
         targets the B cell receptor signaling pathway, specifically as an inhibitor of the delta isoform of PI3K. This agent can alter CD4+ regulatory T cell function and reduce chemokine production [
         <a href="#rid70">
          70,97
         </a>
         ]. It has been studied in combination with
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         in patients with relapsed CLL and as a single agent in patients with relapsed indolent lymphoma [
         <a href="#rid98">
          98-101
         </a>
         ]. In a trial of idelalisib for CLL, pneumonia occurred in 6 percent of patients, febrile neutropenia in 5 percent,
         <em>
          Pneumocystis
         </em>
         pneumonia in 3 percent, and neutropenia in 3 percent, with all being grade 1 or 2 toxicities [
         <a href="#rid98">
          98
         </a>
         ]. In a trial of idelalisib for indolent lymphomas, neutropenia was seen in 56 percent of patients (grade ≥3 in 27 percent), pneumonia in 11 percent (grade ≥3 in 7 percent), and upper respiratory tract infections in 14 percent (all grade 1 or 2) [
         <a href="#rid99">
          99
         </a>
         ]. Grade 3 or 4 pneumonia rates have approached 20 percent in some series [
         <a href="#rid100">
          100,101
         </a>
         ]. No antimicrobial prophylaxis was mandated in clinical trials.
        </p>
        <p>
         In 2016, seven clinical trials of
         <a class="drug drug_general" data-topicid="96416" href="/z/d/drug information/96416.html" rel="external">
          idelalisib
         </a>
         used in combination with other agents for CLL or indolent non-Hodgkin lymphoma were halted due to an increase in serious adverse events and fatalities in patients receiving idelalisib [
         <a href="#rid102">
          102
         </a>
         ]. The majority of adverse events were infections, including sepsis and pneumonia. In particular, an increase in cases of
         <em>
          Pneumocystis
         </em>
         pneumonia and CMV infection was observed in both treatment-naïve and previously treated patients enrolled in three clinical trials of idelalisib used in combination with other agents [
         <a href="#rid103">
          103,104
         </a>
         ]. In a retrospective analysis describing 2198 patients with CLL or indolent non-Hodgkin lymphoma across eight studies, the overall incidence of
         <em>
          Pneumocystis
         </em>
         pneumonia was 2.5 percent in patients receiving an idelalisib-containing regimen (idelalisib alone or in combination with an anti-CD20 monoclonal antibody or
         <a class="drug drug_general" data-topicid="9323" href="/z/d/drug information/9323.html" rel="external">
          bendamustine
         </a>
         +
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         ) versus 0.2 percent in those in a regimen without idelalisib (an anti-CD20 monoclonal antibody +/- bendamustine) [
         <a href="#rid105">
          105
         </a>
         ]. The median time to
         <em>
          Pneumocystis
         </em>
         pneumonia was 141 days after initiation of therapy.
        </p>
        <p>
         Therapy with
         <a class="drug drug_general" data-topicid="96416" href="/z/d/drug information/96416.html" rel="external">
          idelalisib
         </a>
         plus
         <a class="drug drug_general" data-topicid="9523" href="/z/d/drug information/9523.html" rel="external">
          ofatumumab
         </a>
         in previously treated patients with chronic lymphocytic leukemia was associated with grade 3 to 4 neutropenia in 34 percent of patients and grade 3 to 4 pneumonia in 14 percent of patients, compared to 16 percent and 8 percent, respectively, in patients receiving single agent ofatumumab alone [
         <a href="#rid104">
          104
         </a>
         ]. Serious infections were more common with combination therapy than with single agent ofatumumab, including sepsis (11 percent versus 1 percent),
         <em>
          Pneumocystis
         </em>
         infections (5 percent versus 1 percent), urinary tract infections (4 percent versus 0 percent), and cytomegalovirus infection (2 percent versus 0 percent). Pneumonia is one of the most common infectious complications associated with idelalisib use, with a reported incidence of approximately 20 percent; the majority of cases are grade ≥3 [
         <a href="#rid106">
          106
         </a>
         ]. Other opportunistic infections, including cases of PML (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC7289788%2F%23B255&amp;token=wEsKVFvqlKzpT%2BqOtddW%2F9WyS2%2BmbISD1cPa9SCgRnci8vyKZ2%2Fmnf2fB28fHUVWXFwXe%2FJT%2BbrW9%2Bfw%2FbTEvtyiOtwGnsHzVDZkDd5apEw%3D&amp;TOPIC_ID=95716" target="_blank">
          255
         </a>
         ) and disseminated herpes zoster infection, have been reported in patients with CLL receiving idelalisib [
         <a href="#rid87">
          87
         </a>
         ]. At present, idelalisib is approved only for the therapy of relapsed chronic lymphocytic leukemia, in combination with
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         . Recommendations for prophylaxis and monitoring are presented separately(See
         <a class="medical medical_review" href="/z/d/html/1405.html" rel="external">
          "Prevention of infections in patients with chronic lymphocytic leukemia", section on 'Bruton tyrosine kinase and phosphatidylinositol 3-kinase inhibitors'
         </a>
         .)
        </p>
        <p>
         A small number of cases of PML in patients receiving
         <a class="drug drug_general" data-topicid="96416" href="/z/d/drug information/96416.html" rel="external">
          idelalisib
         </a>
         and
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         have occurred. Although rituximab is known to be associated with PML, the number of cases reported may be greater than expected from rituximab; this raises concern that idelalisib might increase the risk of PML. However, using the US Food and Drug Administration's Adverse Event Reporting System (FAERS) database, no increase in the risk of PML was observed with idelalisib. Further study is necessary to assess whether idelalisib itself increases the risk of PML. (See
         <a class="local">
          'Anti-CD20 monoclonal antibodies'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H741373654">
         <span class="h2">
          Duvelisib
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="119167" href="/z/d/drug information/119167.html" rel="external">
          Duvelisib
         </a>
         is an inhibitor of PI3K delta and gamma isoforms that has been approved by the US Food and Drug Administration as a single agent for the treatment of patients with relapsed CLL/small lymphocytic leukemia who have received at least two prior therapies [
         <a href="#rid107">
          107
         </a>
         ]. In the manufacturer's safety analysis, serious infections occurred in 137 of 442 patients (31 percent) receiving duvelisib, including 18 fatal infections (4 percent). The most common serious infections were pneumonia and sepsis. Serious, including fatal,
         <em>
          Pneumocystis
         </em>
         infection and CMV reactivation or infection each occurred in 1 percent of patients. Median time to onset of infection of any grade was three months, with 75 percent of cases occurring within six months of starting the drug. In one review, infections were reported in 70 percent of patients with relapsed/refractory CLL receiving duvelisib, including pneumonia in 18 percent and upper respiratory infections in 16 percent [
         <a href="#rid108">
          108
         </a>
         ]. Reported respiratory tract infections included aspergillosis, pseudomonal pneumonia, and
         <em>
          Pneumocystis
         </em>
         pneumonia, the last occurring in patients not receiving appropriate prophylaxis. (See
         <a class="medical medical_review" href="/z/d/html/1405.html" rel="external">
          "Prevention of infections in patients with chronic lymphocytic leukemia", section on 'Bruton tyrosine kinase and phosphatidylinositol 3-kinase inhibitors'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1891148722">
         <span class="h2">
          Lenalidomide
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">
          Lenalidomide
         </a>
         , an immunomodulatory agent, has been used in the treatment of patients with multiple myeloma, certain subtypes of non-Hodgkin lymphoma such as mantle cell lymphoma, and CLL, the last as part of clinical trials. Based upon review of the trial data, it appears that lenalidomide therapy causes no specific immune dysfunction that would increase the risk of opportunistic infections in these patients [
         <a href="#rid109">
          109
         </a>
         ]. As such, no routine antimicrobial prophylaxis is generally given to patients receiving this agent. However, this agent is not approved for therapy of CLL patients outside of clinical trials.
        </p>
        <p class="headingAnchor" id="H1721476370">
         <span class="h2">
          Venetoclax
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="107696" href="/z/d/drug information/107696.html" rel="external">
          Venetoclax
         </a>
         is a B cell leukemia/lymphoma 2 (BCL-2) inhibitor that is approved for therapy of treatment-naïve CLL patients in combination with either
         <a class="drug drug_general" data-topicid="91388" href="/z/d/drug information/91388.html" rel="external">
          obinutuzumab
         </a>
         or
         <a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">
          ibrutinib
         </a>
         , and in previously treated CLL patients as a single agent, or in combination with either
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         or ibrutinib [
         <a href="#rid110">
          110-113
         </a>
         ].
        </p>
        <p>
         This agent impacts immune function, causing depletion of dendritic cells and reduction in interferon-alpha production (in animal models) as well as reductions in the absolute lymphocyte count [
         <a href="#rid70">
          70
         </a>
         ]. Grade 3 or higher neutropenia occurs in 40 to 50 percent of patients [
         <a href="#rid114">
          114
         </a>
         ]. In the manufacturer's integrated safety analysis of 330 patients enrolled in phase I or II trials, 70 percent of patients had infections, most commonly upper respiratory tract infections (23 percent), pneumonia (11 percent), and nasopharyngitis (10 percent) [
         <a href="#rid70">
          70
         </a>
         ]. Opportunistic infections occurred in 3.6 percent of patients and included invasive aspergillosis,
         <em>
          Pneumocystis
         </em>
         infection, oral/esophageal candidiasis, ocular toxoplasmosis, nocardiosis, herpes pharyngitis, and multidermatomal herpes zoster. When given in combination with
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         , the incidence of neutropenic fever was 12 percent [
         <a href="#rid110">
          110
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1202249">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immune defects
         </strong>
         –
         <strong>
         </strong>
         Infections have a major impact on the clinical course of patients with chronic lymphocytic leukemia (CLL). Patients with CLL have inherent immune defects in humoral and cell-mediated immunity that are related to the primary disease process, including hypogammaglobulinemia, abnormalities in T cell subsets, and defects in complement activity and neutrophil/monocyte function. Therapy-related immunosuppression has further impact on immune function in these patients. (See
         <a class="medical medical_review" href="/z/d/html/1405.html" rel="external">
          "Prevention of infections in patients with chronic lymphocytic leukemia", section on 'Introduction'
         </a>
         and
         <a class="local">
          'Immune defects'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Spectrum of infections
         </strong>
         –
         <strong>
         </strong>
         The spectrum of infections in CLL patients has changed over the past several decades with the introduction of CLL therapies that have specific effects on immune function, particularly on cell-mediated immunity. The infectious complications seen in these patients have evolved in relation to specific agents used. (See
         <a class="local">
          'Spectrum of infections'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Alkylating agents
         </strong>
         –
         <strong>
         </strong>
         Treatment-naïve patients and patients treated with alkylating agents are at increased risk for bacterial infections caused by common pathogens, such as
         <em>
          Staphylococcus aureus
         </em>
         ,
         <em>
          Streptococcus pneumoniae
         </em>
         ,
         <em>
          Haemophilus influenzae
         </em>
         ,
         <em>
          Escherichia coli
         </em>
         ,
         <em>
          Klebsiella pneumoniae
         </em>
         , and
         <em>
          Pseudomonas aeruginosa
         </em>
         . Recurrent bacterial infections with a mucosal origin (respiratory tract, urinary tract) are common. (See
         <a class="local">
          'Spectrum of infections'
         </a>
         above and
         <a class="local">
          'Alkylating agents'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Purine analogs
         </strong>
         –
         <strong>
         </strong>
         With the use of purine analogs (eg,
         <a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">
          fludarabine
         </a>
         ), which result in quantitative and qualitative T cell abnormalities, a wider spectrum of infectious complications has emerged compared with what has been seen with alkylating agents. In patients receiving a purine analog, in addition to common bacterial infections, opportunistic infections caused by organisms such as
         <em>
          Listeria,
         </em>
         mycobacteria,
         <em>
          Nocardia, Candida
         </em>
         ,
         <em>
          Aspergillus
         </em>
         ,
         <em>
          Cryptococcus
         </em>
         ,
         <em>
          Pneumocystis
         </em>
         , and herpesviruses (herpes simplex virus, varicella-zoster virus, and cytomegalovirus [CMV]), have been reported. (See
         <a class="local">
          'Purine analogs'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Anti-CD20 monoclonal antibodies
         </strong>
         –
         <strong>
         </strong>
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          Rituximab
         </a>
         ,
         <a class="drug drug_general" data-topicid="9523" href="/z/d/drug information/9523.html" rel="external">
          ofatumumab
         </a>
         , and
         <a class="drug drug_general" data-topicid="91388" href="/z/d/drug information/91388.html" rel="external">
          obinutuzumab
         </a>
         are anti-CD20 monoclonal antibodies that cause a transient reduction in the B cell count. Grade 3 or 4 (severe) infections and opportunistic infections are uncommon with anti-CD20 monotherapy. However, hepatitis B reactivation may occur among patients positive for hepatitis B surface antigen (HbsAg) or hepatitis B core antibody (anti-HBc). Progressive multifocal leukoencephalopathy has also been reported in patients receiving an anti-CD20 monoclonal antibody. (See
         <a class="local">
          'Anti-CD20 monoclonal antibodies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">
          Alemtuzumab
         </a>
         – Therapy with alemtuzumab, an anti-CD52 monoclonal antibody, is associated with profound defects in cell-mediated immunity as well as neutropenia. Alemtuzumab has been associated with a wide range of infections, including bacterial, viral, fungal, and protozoal infections. Severe infections have included
         <em>
          Aspergillus,
         </em>
         Mucorales
         <em>
          , Candida
         </em>
         ,
         <em>
          Listeria
         </em>
         ,
         <em>
          Pneumocystis
         </em>
         , and CMV. CMV reactivation/disease is the most significant infectious complication occurring with this agent. (See
         <a class="local">
          'Alemtuzumab'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Bruton tyrosine kinase and phosphatidylinositol 3-kinase inhibitors
         </strong>
         –
         <strong>
         </strong>
         There is limited but increasing evidence suggesting that
         <a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">
          ibrutinib
         </a>
         is associated with invasive fungal infections, including
         <em>
          Pneumocystis
         </em>
         pneumonia, invasive aspergillosis, and cryptococcosis, and
         <a class="drug drug_general" data-topicid="96416" href="/z/d/drug information/96416.html" rel="external">
          idelalisib
         </a>
         and
         <a class="drug drug_general" data-topicid="119167" href="/z/d/drug information/119167.html" rel="external">
          duvelisib
         </a>
         are associated with
         <em>
          Pneumocystis
         </em>
         and CMV infections. (See
         <a class="local">
          'Bruton tyrosine kinase inhibitors'
         </a>
         above and
         <a class="local">
          'Phosphatidylinositol 3-kinase inhibitors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">
          Lenalidomide
         </a>
         <strong>
          and
         </strong>
         <a class="drug drug_general" data-topicid="107696" href="/z/d/drug information/107696.html" rel="external">
          venetoclax
         </a>
         <strong>
         </strong>
         –
         <strong>
         </strong>
         Therapy with lenalidomide or venetoclax has not been associated with opportunistic infections. (See
         <a class="local">
          'Lenalidomide'
         </a>
         above and
         <a class="local">
          'Venetoclax'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevention of infections
         </strong>
         –
         <strong>
         </strong>
         The approach to prevention of infections in patients with CLL is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/1405.html" rel="external">
          "Prevention of infections in patients with chronic lymphocytic leukemia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H12914680">
         <span class="h1">
          ACKNOWLEDGMENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Elias Anaissie, MD, and Kieren A Marr, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Wadhwa PD, Morrison VA. Infectious complications of chronic lymphocytic leukemia. Semin Oncol 2006; 33:240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ravandi F, O'Brien S. Immune defects in patients with chronic lymphocytic leukemia. Cancer Immunol Immunother 2006; 55:197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hilal T, Gea-Banacloche JC, Leis JF. Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: Linking mechanisms with infections. Blood Rev 2018; 32:387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sun C, Tian X, Lee YS, et al. Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Blood 2015; 126:2213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aittoniemi J, Miettinen A, Laine S, et al. Opsonising immunoglobulins and mannan-binding lectin in chronic lymphocytic leukemia. Leuk Lymphoma 1999; 34:381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morrison VA, Hibbs JR, Janoff EN. Systemic and mucosal immunoglobulin levels and risk of infection in patients with chronic lymphocytic leukemia and multiple myeloma. Blood 1996; 88:240a.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sinisalo M, Aittoniemi J, Koski T, et al. Similar humoral immunity parameters in chronic lymphocytic leukemia patients independent of VH gene mutation status. Leuk Lymphoma 2004; 45:2451.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Francis S, Karanth M, Pratt G, et al. The effect of immunoglobulin VH gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia. Cancer 2006; 107:1023.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000; 343:1750.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Brien S, Kantarjian H, Beran M, et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood 1993; 82:1695.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keating MJ, O'Brien S, Kantarjian H, et al. Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood 1993; 81:2878.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keating MJ, O'Brien S, Lerner S, et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 1998; 92:1165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anaissie E, Kontoyiannis DP, Kantarjian H, et al. Listeriosis in patients with chronic lymphocytic leukemia who were treated with fludarabine and prednisone. Ann Intern Med 1992; 117:466.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morrison VA, Rai KR, Peterson BL, et al. Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011. J Clin Oncol 2001; 19:3611.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anaissie EJ, Kontoyiannis DP, O'Brien S, et al. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med 1998; 129:559.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frank DA, Mahajan S, Ritz J. Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Nat Med 1999; 5:444.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morra E, Nosari A, Montillo M. Infectious complications in chronic lymphocytic leukaemia. Hematol Cell Ther 1999; 41:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hensel M, Kornacker M, Yammeni S, et al. Disease activity and pretreatment, rather than hypogammaglobulinaemia, are major risk factors for infectious complications in patients with chronic lymphocytic leukaemia. Br J Haematol 2003; 122:600.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Molteni A, Nosari A, Montillo M, et al. Multiple lines of chemotherapy are the main risk factor for severe infections in patients with chronic lymphocytic leukemia with febrile episodes. Haematologica 2005; 90:1145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leporrier M, Chevret S, Cazin B, et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 2001; 98:2319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steurer M, Pall G, Richards S, et al. Single-agent purine analogues for the treatment of chronic lymphocytic leukaemia: a systematic review and meta-analysis. Cancer Treat Rev 2006; 32:377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flinn IW, Byrd JC, Morrison C, et al. Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood 2000; 96:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flinn IW, Neuberg DS, Grever MR, et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol 2007; 25:793.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hallek M, Schmitt B, Wilhelm M, et al. Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group. Br J Haematol 2001; 114:342.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eichhorst BF, Busch R, Hopfinger G, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006; 107:885.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eichhorst BF, Busch R, Schweighofer C, et al. Due to low infection rates no routine anti-infective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine-based first line therapy. Br J Haematol 2007; 136:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kowal M, Dmoszyńska A, Lewandowski K, et al. Efficacy and safety of fludarabine and cyclophosphamide combined therapy in patients with refractory/recurrent B-cell chronic lymphocytic leukaemia (B-CLL)-Polish multicentre study. Leuk Lymphoma 2004; 45:1159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jindra P, Koza V, Boudová L, et al. Epstein-Barr virus-associated B-cell lymphoproliferative disorder in CLL patients after treatment with fludarabine and cyclophosphamide followed by high-dose chemotherapy with autologous stem cell transplantation. Bone Marrow Transplant 2003; 31:951.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robak T, Błoński JZ, Urbańska-Ryś H, et al. 2-Chlorodeoxyadenosine (Cladribine) in the treatment of patients with chronic lymphocytic leukemia 55 years old and younger. Leukemia 1999; 13:518.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robak T, Błasińska-Morawiec M, Błoński JZ, Dmoszyńska A. 2-Chlorodeoxyadenosine (cladribine) in the treatment of elderly patients with B-cell chronic lymphocytic leukemia. Leuk Lymphoma 1999; 34:151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Byrd JC, Peterson B, Piro L, et al. A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211. Leukemia 2003; 17:323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piro LD, Carrera CJ, Beutler E, Carson DA. 2-Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia. Blood 1988; 72:1069.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robak T, Bloński JZ, Kasznicki M, et al. Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukaemia - updated results of the multicentre study of 378 patients. Br J Haematol 2000; 108:357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robak T, Bloński JZ, Kasznicki M, et al. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood 2000; 96:2723.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dillman RO, Mick R, McIntyre OR. Pentostatin in chronic lymphocytic leukemia: a phase II trial of Cancer and Leukemia group B. J Clin Oncol 1989; 7:433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oken MM, Lee S, Kay NE, et al. Pentostatin, chlorambucil and prednisone therapy for B-chronic lymphocytic leukemia: a phase I/II study by the Eastern Cooperative Oncology Group study E1488. Leuk Lymphoma 2004; 45:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lamanna N, Kalaycio M, Maslak P, et al. Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol 2006; 24:1575.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shanafelt TD, Lin T, Geyer SM, et al. Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia. Cancer 2007; 109:2291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hainsworth JD, Litchy S, Barton JH, et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2003; 21:1746.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003; 101:6.
          </a>
         </li>
         <li class="breakAll">
          US Food and Drug Administration. FDA drug safety communication: Boxed warning and new recommendations to decrease risk of hepatitis B reactivation with the immune-suppressing and anti-cancer drugs Arzerra (ofatumumab) and Rituxan (rituximab). https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-boxed-warning-and-new-recommendations-decrease-risk-hepatitis-b (Accessed on October 18, 2023).
         </li>
         <li class="breakAll">
          Rituxan (rituximab) injection, for intravenous use. US Food &amp; Drug Administration (FDA) approved product information. Revised 2014. US Food &amp; Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103705s5432lbl.pdf (Accessed on October 18, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Al-Sawaf O, Zhang C, Tandon M, et al. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2020; 21:1188.
          </a>
         </li>
         <li class="breakAll">
          Arzerra (ofatumumab) injection, for intravenous use. US Food &amp; Drug Administration (FDA) approved product information. Revised August 2016. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125326s063lbl.pdf (Accessed on October 18, 2023).
         </li>
         <li class="breakAll">
          Gazyva (obinutuzumab) injection, for intravenous infusion. US Food &amp; Drug Administration (FDA) approved product information. Revised June 2014. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125486_s008lbl.pdf (Accessed on October 18, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010; 28:1749.
          </a>
         </li>
         <li class="breakAll">
          ARZERRA (ofatumumab) injection, for intravenous infusion. Highlights of prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125326lbl.pdf (Accessed on October 18, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Munir T, Brown JR, O'Brien S, et al. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol 2019; 94:1353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014; 370:1101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown JR, O'Brien S, Kingsley CD, et al. Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial. Blood 2015; 125:2779.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005; 23:4079.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wierda W, O'Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005; 23:4070.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lundin J, Porwit-MacDonald A, Rossmann ED, et al. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia. Leukemia 2004; 18:484.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lundin J, Osterborg A. Advances in the use of monoclonal antibodies in the therapy of chronic lymphocytic leukemia. Semin Hematol 2004; 41:234.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lozanski G, Heerema NA, Flinn IW, et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004; 103:3278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99:3554.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rai KR, Freter CE, Mercier RJ, et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 2002; 20:3891.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lundin J, Kimby E, Björkholm M, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002; 100:768.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cortelezzi A, Pasquini MC, Sarina B, et al. A pilot study of low-dose subcutaneous alemtuzumab therapy for patients with hemotherapy-refractory chronic lymphocytic leukemia. Haematologica 2005; 90:410.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martin SI, Marty FM, Fiumara K, et al. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis 2006; 43:16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007; 25:5616.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Faderl S, Thomas DA, O'Brien S, et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 2003; 101:3413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elter T, Borchmann P, Schulz H, et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol 2005; 23:7024.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin TS, Donohue KA, Byrd JC, et al. Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101. J Clin Oncol 2010; 28:4500.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Brien SM, Keating MJ, Mocarski ES. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab. Clin Lymphoma Myeloma 2006; 7:125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013; 369:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jaglowski SM, Jones JA, Nagar V, et al. Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study. Blood 2015; 126:842.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams AM, Baran AM, Meacham PJ, et al. Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies. Leuk Lymphoma 2018; 59:625.
          </a>
         </li>
         <li class="breakAll">
          IMBRUVICA (ibrutinib) capsules, for oral use. United States Prescribing Information. Revised January 2017. US Food &amp; Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205552s016lbl.pdf (Accessed on October 18, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reinwald M, Silva JT, Mueller NJ, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors). Clin Microbiol Infect 2018; 24 Suppl 2:S53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Brien S, Furman RR, Coutre SE, et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol 2014; 15:48.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Varughese T, Taur Y, Cohen N, et al. Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer. Clin Infect Dis 2018; 67:687.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rogers KA, Mousa L, Zhao Q, et al. Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies. Leukemia 2019; 33:2527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arthurs B, Wunderle K, Hsu M, Kim S. Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia. Respir Med Case Rep 2017; 21:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chamilos G, Lionakis MS, Kontoyiannis DP. Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways. Clin Infect Dis 2018; 66:140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruchlemer R, Ben Ami R, Lachish T. Ibrutinib for Chronic Lymphocytic Leukemia. N Engl J Med 2016; 374:1593.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lionakis MS, Dunleavy K, Roschewski M, et al. Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma. Cancer Cell 2017; 31:833.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baron M, Zini JM, Challan Belval T, et al. Fungal infections in patients treated with ibrutinib: two unusual cases of invasive aspergillosis and cryptococcal meningoencephalitis. Leuk Lymphoma 2017; 58:2981.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghez D, Calleja A, Protin C, et al. Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. Blood 2018; 131:1955.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahn IE, Jerussi T, Farooqui M, et al. Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib. Blood 2016; 128:1940.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okamoto K, Proia LA, Demarais PL. Disseminated Cryptococcal Disease in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib. Case Rep Infect Dis 2016; 2016:4642831.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Messina JA, Maziarz EK, Spec A, et al. Disseminated Cryptococcosis With Brain Involvement in Patients With Chronic Lymphoid Malignancies on Ibrutinib. Open Forum Infect Dis 2017; 4:ofw261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan TS, Au-Yeung R, Chim CS, et al. Disseminated fusarium infection after ibrutinib therapy in chronic lymphocytic leukaemia. Ann Hematol 2017; 96:871.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Serota DP, Mehta AK, Phadke VK. Invasive Fungal Sinusitis due to Mucor Species in a Patient on Ibrutinib. Clin Infect Dis 2018; 66:1482.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang SY, Ebert T, Jaekel N, et al. Miliary tuberculosis after initiation of ibrutinib in chronic lymphocytic leukemia. Ann Hematol 2015; 94:1419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lutz M, Schulze AB, Rebber E, et al. Progressive Multifocal Leukoencephalopathy after Ibrutinib Therapy for Chronic Lymphocytic Leukemia. Cancer Res Treat 2017; 49:548.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raisch DW, Rafi JA, Chen C, Bennett CL. Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA's adverse event reporting system. Expert Opin Drug Saf 2016; 15:1003.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sun K, Kasparian S, Iyer S, Pingali SR. Cryptococcal meningoencephalitis in patients with mantle cell lymphoma on ibrutinib. Ecancermedicalscience 2018; 12:836.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Jésus Ngoma P, Kabamba B, Dahlqvist G, et al. Occult HBV reactivation induced by ibrutinib treatment: a case report. Acta Gastroenterol Belg 2015; 78:424.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diamantopoulos PT, Psichogiou M, Pantazatou A, et al. Staphylococcus aureus meningitis in a patient with mantle cell lymphoma under treatment with ibrutinib. Ann Hematol 2017; 96:1049.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stein MK, Karri S, Reynolds J, et al. Cutaneous Mucormycosis Following a Bullous Pemphigoid Flare in a Chronic Lymphocytic Leukemia Patient on Ibrutinib. World J Oncol 2018; 9:62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Voshtina E, Huang H, Raj R, Atallah E. Amebic Encephalitis in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib Therapy. Case Rep Hematol 2018; 2018:6514604.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dousa KM, Babiker A, Van Aartsen D, et al. Ibrutinib Therapy and Mycobacterium chelonae Skin and Soft Tissue Infection. Open Forum Infect Dis 2018; 5:ofy168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giridhar KV, Shanafelt T, Tosh PK, et al. Disseminated herpes zoster in chronic lymphocytic leukemia (CLL) patients treated with B-cell receptor pathway inhibitors. Leuk Lymphoma 2017; 58:1973.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kreiniz N, Bejar J, Polliack A, Tadmor T. Severe pneumonia associated with ibrutinib monotherapy for CLL and lymphoma. Hematol Oncol 2018; 36:349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang ML, Jurczak W, Zinzani PL, et al. Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma. J Clin Oncol 2023; 41:3988.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ali K, Soond DR, Pineiro R, et al. Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer. Nature 2014; 510:407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014; 370:997.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gopal AK, Kahl BS, de Vos S, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 2014; 370:1008.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown JR, Byrd JC, Coutre SE, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. Blood 2014; 123:3390.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Brien SM, Lamanna N, Kipps TJ, et al. A phase II study of the selective phosphatidylinositol 3-kinase delta (PI3Kd) inhibitor idelalisib (GS-1101) in combination with rituximab in treatement naive patients &gt;65 years with chronic lymphocytic leukemia or small lymphocytic lymphoma. J Clin Oncol 2013; 31:7005.
          </a>
         </li>
         <li class="breakAll">
          Health Canada. Summary safety review - Zydelig (idelalisib) - Assessing the potential risk of serious infections. http://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/zydelig-eng.php (Accessed on October 18, 2023).
         </li>
         <li class="breakAll">
          Personal communication, Gilead Medical Information Department. (25 March 2016).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones JA, Robak T, Brown JR, et al. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial. Lancet Haematol 2017; 4:e114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sehn LH, Hallek M, Jurczak W, et al.. A retrospective analysis of Pneumocystis jirovecii pneumonia infection in patients receiving idelalisib in clinical trials. Blood 2016; 128:3701.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Weerdt I, Koopmans SM, Kater AP, van Gelder M. Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach. Haematologica 2017; 102:1629.
          </a>
         </li>
         <li class="breakAll">
          Copiktra (duvelisib), capsules for oral use. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211155s000lbl.pdf (Accessed on October 18, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel K, Danilov AV, Pagel JM. Duvelisib for CLL/SLL and follicular non-Hodgkin lymphoma. Blood 2019; 134:1573.
          </a>
         </li>
         <li class="breakAll">
          US Food and Drug Administration. REVLIMID [lenalidomide]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021880s057lbl.pdf (Accessed on October 18, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. N Engl J Med 2018; 378:1107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. N Engl J Med 2019; 380:2225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davids MS, Hallek M, Wierda W, et al. Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. Clin Cancer Res 2018; 24:4371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stephens DM. Venetoclax and obinutuzumab for frontline treatment of chronic lymphocytic leukemia. Blood 2019; 134:1691.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Teh BW, Tam CS, Handunnetti S, et al. Infections in patients with chronic lymphocytic leukaemia: Mitigating risk in the era of targeted therapies. Blood Rev 2018; 32:499.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 95716 Version 27.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16616071" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Infectious complications of chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16025268" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Immune defects in patients with chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29571669" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: Linking mechanisms with infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26337493" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10439375" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Opsonising immunoglobulins and mannan-binding lectin in chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Systemic and mucosal immunoglobulin levels and risk of infection in patients with chronic lymphocytic leukemia and multiple myeloma
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15621758" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Similar humoral immunity parameters in chronic lymphocytic leukemia patients independent of VH gene mutation status.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16862572" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : The effect of immunoglobulin VH gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11114313" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8400226" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8499626" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9694704" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1354425" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Listeriosis in patients with chronic lymphocytic leukemia who were treated with fludarabine and prednisone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11504743" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9758577" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Infections in patients with chronic lymphocytic leukemia treated with fludarabine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10202937" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10543369" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Infectious complications in chronic lymphocytic leukaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12899715" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Disease activity and pretreatment, rather than hypogammaglobulinaemia, are major risk factors for infectious complications in patients with chronic lymphocytic leukaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16079122" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Multiple lines of chemotherapy are the main risk factor for severe infections in patients with chronic lymphocytic leukemia with febrile episodes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11588025" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16793209" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Single-agent purine analogues for the treatment of chronic lymphocytic leukaemia: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10891432" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17283364" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11529853" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16219797" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17083342" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Due to low infection rates no routine anti-infective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine-based first line therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15359995" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Efficacy and safety of fludarabine and cyclophosphamide combined therapy in patients with refractory/recurrent B-cell chronic lymphocytic leukaemia (B-CLL)-Polish multicentre study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12748677" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Epstein-Barr virus-associated B-cell lymphoproliferative disorder in CLL patients after treatment with fludarabine and cyclophosphamide followed by high-dose chemotherapy with autologous stem cell transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10214856" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : 2-Chlorodeoxyadenosine (Cladribine) in the treatment of patients with chronic lymphocytic leukemia 55 years old and younger.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10350343" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : 2-Chlorodeoxyadenosine (cladribine) in the treatment of elderly patients with B-cell chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12592330" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2901280" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : 2-Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10691866" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukaemia - updated results of the multicentre study of 378 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11023504" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2784491" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Pentostatin in chronic lymphocytic leukemia: a phase II trial of Cancer and Leukemia group B.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15061201" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Pentostatin, chlorambucil and prednisone therapy for B-chronic lymphocytic leukemia: a phase I/II study by the Eastern Cooperative Oncology Group study E1488.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16520464" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17514743" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12721250" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12393429" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12393429" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12393429" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32888452" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32888452" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32888452" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20194866" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20194866" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31512258" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24401022" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25769620" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15767648" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15767647" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14749699" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15269883" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Advances in the use of monoclonal antibodies in the therapy of chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14726385" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11986207" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12228210" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12130484" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15749678" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : A pilot study of low-dose subcutaneous alemtuzumab therapy for patients with hemotherapy-refractory chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16758413" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Infectious complications associated with alemtuzumab use for lymphoproliferative disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17984186" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12522009" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16145065" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20697069" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17026823" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23782158" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26116658" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28696801" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28696801" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29454849" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24332241" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29509845" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31086260" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28377877" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29029010" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27096597" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Ibrutinib for Chronic Lymphocytic Leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28552327" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28554246" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Fungal infections in patients treated with ibrutinib: two unusual cases of invasive aspergillosis and cryptococcal meningoencephalitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29437588" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27503501" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27703818" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Disseminated Cryptococcal Disease in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28480254" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Disseminated Cryptococcosis With Brain Involvement in Patients With Chronic Lymphoid Malignancies on Ibrutinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28184982" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Disseminated fusarium infection after ibrutinib therapy in chronic lymphocytic leukaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29186341" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Invasive Fungal Sinusitis due to Mucor Species in a Patient on Ibrutinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25903044" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Miliary tuberculosis after initiation of ibrutinib in chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27456945" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Progressive Multifocal Leukoencephalopathy after Ibrutinib Therapy for Chronic Lymphocytic Leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27268272" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA's adverse event reporting system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29910833" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Cryptococcal meningoencephalitis in patients with mantle cell lymphoma on ibrutinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26712054" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Occult HBV reactivation induced by ibrutinib treatment: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28247056" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Staphylococcus aureus meningitis in a patient with mantle cell lymphoma under treatment with ibrutinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29760835" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Cutaneous Mucormycosis Following a Bullous Pemphigoid Flare in a Chronic Lymphocytic Leukemia Patient on Ibrutinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30155323" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Amebic Encephalitis in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30090839" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Ibrutinib Therapy and Mycobacterium chelonae Skin and Soft Tissue Infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27960571" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Disseminated herpes zoster in chronic lymphocytic leukemia (CLL) patients treated with B-cell receptor pathway inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28156016" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Severe pneumonia associated with ibrutinib monotherapy for CLL and lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37192437" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24919154" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Inactivation of PI(3)K p110δbreaks regulatory T-cell-mediated immune tolerance to cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24450857" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24450858" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : PI3Kδinhibition by idelalisib in patients with relapsed indolent lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24615777" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : A phase II study of the selective phosphatidylinositol 3-kinase delta (PI3Kd) inhibitor idelalisib (GS-1101) in combination with rituximab in treatement naive patients&gt;65 years with chronic lymphocytic leukemia or small lymphocytic lymphoma
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : A phase II study of the selective phosphatidylinositol 3-kinase delta (PI3Kd) inhibitor idelalisib (GS-1101) in combination with rituximab in treatement naive patients&gt;65 years with chronic lymphocytic leukemia or small lymphocytic lymphoma
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : A phase II study of the selective phosphatidylinositol 3-kinase delta (PI3Kd) inhibitor idelalisib (GS-1101) in combination with rituximab in treatement naive patients&gt;65 years with chronic lymphocytic leukemia or small lymphocytic lymphoma
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28257752" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : A retrospective analysis of Pneumocystis jirovecii pneumonia infection in patients receiving idelalisib in clinical trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28775119" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28775119" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31554637" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Duvelisib for CLL/SLL and follicular non-Hodgkin lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31554637" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Duvelisib for CLL/SLL and follicular non-Hodgkin lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29562156" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31166681" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29895707" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31488409" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Venetoclax and obinutuzumab for frontline treatment of chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29709246" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Infections in patients with chronic lymphocytic leukaemia: Mitigating risk in the era of targeted therapies.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
